Brain Cancer Diagnostics Market Size | Global Forecast to 2028

Brain Cancer Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Diagnostic Type (Imaging Test [MRI, CT Scan, PET, and Others], Lumbar Puncture, Biopsy, Molecular Testing, Platform and Services [Sample Slide, Autosampler Unit, Solutions & Platform, and Services], Cerebral Arteriogram, Neurological & Hearing Tests/Neurocognitive Assessments, Electroencephalography (EEG), and Others); Cancer Type (Acoustic Neuroma, Astrocytomas, Craniopharyngiomas, Ganglioneuromas, Glioblastoma Multiforme, Meningiomas, Ependymomas, Oligodendroglioma, Low-Grade Tumors, and Others); End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Diagnostic Centers & Research Institutes, and Others); and Tumor Size (0.2 cm3 to 100 cm3, 101 cm3 to 200 cm3, and Above 200 cm3)

Publication Month : Jun 2022

  • Report Code : TIPRE00024461
  • Category : Medical Device
  • Status : Published
  • No. of Pages : 302
Inquire Before Buy

PRICING

$4550

$3640

The brain cancer diagnostics market is projected to reach US$ 7,378.57 Million by 2028 from US$ 1,639.10 Million in 2022; it is estimated to grow at a CAGR of 28.5% from 2022 to 2028.

Brain cancers are caused due to extracellular growth of the cells in the brain that causes tumors. The tumor includes primary brain tumors and secondary brain tumors. Primary brain tumors are formed in the brain and do not spread to other body parts, whereas secondary tumors, also known as metastases, are those cancers that began in another part of the body. Brain tumors are categorized into 40 major types that are further classified into two major groups, including benign, i.e., slow-growing and have less possibility to spread, and malignant, i.e., cancerous, and more likely to spread.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Brain Cancer Diagnostics Market: Strategic Insights

brain-cancer-diagnostics-market
Market Size Value inUS$ 1,639.10 Million in 2022
Market Size Value byUS$ 7,378.57 Million by 2028
Growth rateCAGR of 28.5% from 2022 to 2028.
Forecast Period2022-2028
Base Year2022
Analyst Image

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst Image  Speak to Analyst

The brain cancer diagnostics market is segmented into diagnostic type, cancer type, end user, tumor size, and geography. The market , by geography, is broadly segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South and Central America. The report offers in-depth insights into the market, emphasizing parameters such as market trends, technological advancements, and market dynamics, along with an analysis of the competitive landscape of leading market players.        

Lucrative Regions for Brain cancer diagnostics market

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities

Market Insights

Rising Incidences of Brain Tumors Contributes Significantly to Market Growth

According to the American Society of Clinical Oncology (ASCO), in 2021, around 24,530 adults (13,840 men and 10,690 women) were diagnosed with primary cancerous tumors of the brain and spinal cord in the US. In a person's lifetime, the chances of having this form of tumor are fewer than 1%. Most primary central nervous system (CNS) malignancies are brain tumors, which account for 85% to 90% of all cases. Brain tumors can be fatal, severely impact the quality of life, and ultimately transform a patient's and their family's lives.

Similarly, Cancer Research UK estimated that around 12,288 new cases of brain, other CNS, and intracranial tumors are diagnosed in the UK each year, which makes it around 34 cases per day (2016–2018). Brain tumors, other central nervous systems, and intracranial tumors are the ninth most common malignancies in the UK, accounting for 3% of all new cancer cases (2016–2018). Also, it is the 7th most common cancer in females in the UK, with around 6,400 new cases during 2016–2018. Similarly, in males, brain, other CNS, and intracranial tumors are the 11th most common cancer, with about 5,800 new cases in the UK during 2016–2018. Incidence rates for brain tumors are highest in people aged 85 to 89 (2016-2018) in the UK.

According to the American Association of Neurological Surgeons, glioblastoma is the most common malignant brain and other CNS tumor, accounting for 47.7% of all cases; the incidence of glioblastoma is 3.21 per 100,000 people. According to Cancer Australia, around 1,879 new cases of brain cancer were diagnosed in Australia in 2020.

Early detection of tumors often provides more treatment options. Advanced imaging technology can pinpoint the location of brain tumors. Intraoperative MRI can also guide tissue biopsy and tumor resection during surgery. Magnetic resonance spectroscopy (MRS) is used to examine the chemical characteristics of tumors. Thus, the increase in the prevalence of brain cancer worldwide highly demands brain cancer diagnostic tools.

Diagnostic Type-Based Insights

Based on diagnostic type, the brain cancer diagnostics market is segmented into imaging test, lumbar puncture, biopsy, molecular testing, platform and services, cerebral arteriogram, neurological and hearing tests/neurocognitive assessments, electroencephalography (EEG), and others. Furthermore, the imaging test segment is sub-segmented into MRI, CT Scan, PET, and others. Similarly, the platform and services segment is sub-segmented into sample slide, autosampler unit, solutions and platform, and services. In 2022, the imaging test segment is likely to account for the largest share of the market. However, the platform and services segment is anticipated to register the highest CAGR in the brain cancer diagnostics market  during the forecast period of 2022 to 2028.

Cancer Type-Based Insights

The global brain cancer diagnostics market , based on cancer type, is segmented into acoustic neuroma, astrocytomas, craniopharyngiomas, ganglioneuromas, glioblastoma multiforme, meningiomas, ependymomas, oligodendroglioma, low-grade tumors, and other brain cancer types. In 2022, the glioblastoma multiforme segment is likely to hold the largest share of the market. Moreover, the same segment is expected to witness growth in its demand at the fastest CAGR from 2022 to 2028, owing to the rise in the incidence of glioblastoma multiforme globally.

Tumor Size-Based Insights

The global brain cancer diagnostics market , based on tumor size, is segmented into 0.2 cm3 to 100 cm3, 101 cm3 to 200 cm3, and above 200 cm3. In 2022, the 0.2 cm3 to 100 cm3 segment is likely to hold the largest share of the market. Moreover, the 0.2 cm3 to 100 cm3 segment is expected to witness growth in its demand at the fastest CAGR from 2022 to 2028, owing to the rise in the detection and diagnosis of various medical conditions globally.

End User-Based Insights

Based on end user, the brain cancer diagnostics market is segmented into hospitals, specialty clinics, ambulatory surgical centers, diagnostic centers & research institutes, and others. In 2022, the hospitals segment is likely to hold the largest share of the market. Moreover, the specialty clinics segment is expected to witness growth in its demand at the fastest CAGR of 29.4% from 2022 to 2028, owing to the adoption of advanced technologies for brain cancer diagnosis by hospitals globally.

Brain cancer diagnostics market , by Diagnostic Type – 2022 and 2028

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities

Product launches, mergers and acquisitions are highly adopted strategies by the global brain cancer diagnostics market players. A few of the recent key market developments are listed below: 

In September 2021, BioReference Laboratories, Inc., an OPKO Health company, along with its specialty oncology division, GenPath, announced the launch of OnkoSight AdvancedTM, a next-generation sequencing (NGS) assay that enables revolutionary deoxyribonucleic acid (DNA) mutational profiling of tumor samples.

Geography-Based Insights

The global brain cancer diagnostics market , by geography, is broadly segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and the Rest of APAC), the Middle East & Africa (Saudi Arabia, the UAE, South Africa, and the Rest of MEA), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Company -Based Insights

THERMO FISHER SCIENTIFIC INC; Siemens Healthineers AG; GE Healthcare; MDxHealth; NantOmics; Biocept, Inc.; Koninklijke Philips N.V.; Canon Medical Systems; Hitachi, Ltd.; Neusoft Medical Systems; KITZ HEIDELBERG; GENPATH; NVIDIA CORPORATION; ONCORA MEDICAL; BIOMIND; SOPHIA AND ONCODNA; Clinspec Diagnostics; Raindance Technologies, Inc; ROCHE DIAGNOSTICS; and Illumina, Inc are among the leading companies operating in the brain cancer diagnostics market

Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

Diagnostic Type; Cancer Typ; End User ; and Tumor Size

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States

Frequently Asked Questions


Who are the key players in the brain cancer diagnostics market?

The brain cancer diagnostics market majorly consists of players such as THERMO FISHER SCIENTIFIC INC, Siemens Healthineers AG, GE Healthcare, MDxHealth, NantOmics, Biocept, Inc., Koninklijke Philips N.V., Canon Medical Systems, Hitachi, Ltd., Neusoft Medical Systems, KITZ HEIDELBERG, GENPATH, NVIDIA CORPORATION, ONCORA MEDICAL, BIOMIND, SOPHIA AND ONCODNA, Clinspec Diagnostics, Raindance Technologies, Inc, ROCHE DIAGNOSTICS, Illumina, Inc.

Which diagnostics type held the largest share in the brain cancer diagnostics market?

In 2021, the imaging test held the largest share of the market by drug development type. It is expected to report a higher CAGR of 29.5% during 2021–2028.

What is the market CAGR value of the brain cancer diagnostics market during the forecast period?

The CAGR value of the brain cancer diagnostics market during the forecasted period of 2021–2028 is 28.5%.

Which cancer type led the brain cancer diagnostics market?

In 2021, the glioblastoma multiforme segment accounted for the largest share of the market; it is further expected to continue its dominance over the forecast period. The major driving factor for the growth of the glioblastoma multiforme segment is the growing incidence of glioblastoma multiforme. Moreover, the increasing awareness about brain cancer diagnostics among the population is one of the significant factors in the growth of the glioblastoma multiforme segment.

What are the driving factors for the brain cancer diagnostics market across the globe?

Key factors driving the growth of this market are the increase in brain cancer worldwide and the rise in cigarette smokers expected to drive the market during the forecast period.

What are brain cancer diagnostics?

Brain cancers are caused due to extracellular growth of the cells in the brain that causes tumors. The tumor includes primary brain tumors and secondary brain tumors. Primary brain tumors are formed in the brain and do not spread to other body parts, whereas secondary tumors, also known as metastases, are those cancers that began in another part of the body. Brain tumors are categorized into 40 major types that are further classified into two major groups, including benign, i.e., slow-growing and have less possibility to spread, and malignant, i.e., cancerous, and more likely to spread.

Which are the top companies that hold the market share in the brain cancer diagnostics market?

Koninklijke Philips N.V. and GE Healthcare are the top two companies that hold huge market shares in the brain cancer diagnostics market.

The List of Companies - Brain Cancer Diagnostics Market

  1. THERMO FISHER SCIENTIFIC INC
  2. Siemens Healthineers AG
  3. GE Healthcare
  4.  MDxHealth
  5. NantOmics
  6. Biocept, Inc.
  7. Koninklijke Philips N.V.
  8. Canon Medical Systems
  9. Hitachi, Ltd
  10. Neusoft Medical Systems
  11. KITZ HEIDELBERG
  12. GENPATH
  13. NVIDIA CORPORATION
  14. ONCORA MEDICAL
  15. BIOMIND
  16. SOPHIA AND ONCODNA
  17. Clinspec Diagnostics
  18. Raindance Technologies, Inc
  19. ROCHE DIAGNOSTICS
  20. Illumina, Inc.

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Brain Cancer Diagnostics Market